Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for Capricor Therapeutics (CAPR) over the last 15 years, with Dec 2024 value amounting to $1.9 million.

  • Capricor Therapeutics' Change in Accured Expenses rose 168.83% to $971,647 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 2201.34%. This contributed to the annual value of $1.9 million for FY2024, which is 46.35% up from last year.
  • Capricor Therapeutics' Change in Accured Expenses amounted to $1.9 million in FY2024, which was up 46.35% from $1.3 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Change in Accured Expenses peaked at $1.9 million during FY2024, and registered a low of $590,416 during FY2021.
  • In the last 3 years, Capricor Therapeutics' Change in Accured Expenses had a median value of $1.7 million in 2022 and averaged $1.7 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 615.06% in 2020, then crashed by 67.91% in 2021.
  • Over the past 5 years, Capricor Therapeutics' Change in Accured Expenses (Yearly) stood at $1.8 million in 2020, then tumbled by 67.91% to $590,416 in 2021, then skyrocketed by 191.03% to $1.7 million in 2022, then fell by 22.81% to $1.3 million in 2023, then spiked by 46.35% to $1.9 million in 2024.